Bli medlem
Bli medlem

Du är här

2016-12-15

TiGenix: TiGenix raises $35.65 million gross proceeds with NASDAQ IPO

PRESS RELEASE

REGULATED INFORMATION

TiGenix raises $35.65 million gross proceeds with NASDAQ IPO

Leuven (BELGIUM) - December 15, 2016, 3:00h CET - TiGenix NV (Euronext
Brussels: TIG; "TiGenix"), an advanced biopharmaceutical company focused on
developing and commercializing novel therapeutics from its proprietary
platforms of allogeneic expanded stem cells, announced today the pricing of
its initial public offering in the United States (the "Offering") totalling
$35.65 million gross proceeds from the sale of 2,300,000 American Depository
Shares ("ADSs"), representing 46,000,000 ordinary shares, at a price to the
public of $15.50 per ADS.

In connection with the Offering, TiGenix has granted the underwriters a 30-day
option to purchase up to an additional 345,000 ADSs, representing 6,900,000
ordinary shares, to cover over-allotments, if any.

The closing of the Offering is expected to occur on December 20, 2016, subject
to the satisfaction of customary closing conditions.

Each of the ADSs offered represents the right to receive twenty (20) ordinary
shares.

TiGenix's ordinary shares are currently listed on Euronext Brussels. The ADSs
are expected to begin trading on NASDAQ on December 15, 2016 under the symbol
"TIG".

BofA Merrill Lynch and Cowen and Company, LLC are acting as joint book-running
managers, Canaccord Genuity is acting as lead manager and BTIG is acting as
co-manager for the Offering.

The Offering of ADSs will be made only by means of a prospectus. A copy of the
final prospectus, when available, can be obtained from BofA Merrill Lynch,
NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001,
Attn: Prospectus Department, Email:dg.prospectus_requests@baml.comand from
Cowen and Company LLC, c/o Broadridge Financial Services, 1155 Long Island
Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at
(631) 274-2806 or by fax at (631) 254-7140.

A registration statement relating to these securities was filed with and
declared effective by the U.S. Securities and Exchange Commission on December
14, 2016. The registration statement can be accessed through the SEC's
website atwww.sec.gov.

This press release is for information purposes only and does not constitute,
and should not be construed as, an offer to sell or the solicitation of an
offer to buy or subscribe to any securities of TiGenix, nor shall there be
any sale of securities in any jurisdiction in which such offer, solicitation
or sale is not permitted or to any person or entity to whom it is unlawful to
make such offer, solicitation or sale. This press release is not for
publication or distribution, directly or indirectly, in or into any state or
jurisdiction into which doing so would be unlawful.

For more information, please contact:

TiGenix
Claudia D'Augusta
Chief Financial Officer
T: +34 91 804 92 64
claudia.daugusta@tigenix.com

About TiGenix
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company
focused on developing and commercializing novel therapeutics from its
proprietary platforms of allogeneic, or donor-derived, expanded stem cells.
Our lead product candidate from the adipose-derived stem cell technology
platform is Cx601, which is in registration with the European Medicines
Agency for the treatment of complex perianal fistulas in Crohn's disease
patients. Our adipose-derived stem cell product candidate Cx611 has completed
a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid
arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead
cellular product candidate, AlloCSC-01, is currently in a Phase II clinical
trial in Acute Myocardial Infarction (AMI). In addition, the second product
candidate from the cardiac stem cell-based platform acquired from
Coretherapix, AlloCSC-02, is being developed in a chronic indication. On July
4, 2016, TiGenix entered into a licensing agreement with Takeda, a large
pharmaceutical company active in gastroenterology, under which Takeda
acquired the exclusive right to commercialize Cx601 for complex perianal
fistulas outside the United States. TiGenix is headquartered in Leuven
(Belgium) and has operations in Madrid (Spain).

Forward-looking information
This press release may contain forward-looking statements and estimates with
respect to the anticipated future performance of TiGenix and the market in
which it operates. Certain of these statements, forecasts and estimates can
be recognised by the use of words such as, without limitation, "believes",
"anticipates", "expects", "intends", "plans", "seeks", "estimates", "may",
"will" and "continue" and similar expressions. They include all matters that
are not historical facts. Such statements, forecasts and estimates are based
on various assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable when made but
may or may not prove to be correct. Actual events are difficult to predict
and may depend upon factors that are beyond TiGenix's control. Therefore,
actual results, the financial condition, performance or achievements of
TiGenix, or industry results, may turn out to be materially different from
any future results, performance or achievements expressed or implied by such
statements, forecasts and estimates. Given these uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as of the date
of the publication of this press release. TiGenix disclaims any obligation to
update any such forward-looking statement, forecast or estimates to reflect
any change in TiGenix's expectations with regard thereto, or any change in
events, conditions or circumstances on which any such statement, forecast or
estimate is based, except to the extent required by applicable law.

IMPORTANT INFORMATION
No public offering will be made and no one has taken any action that would, or
is intended to, permit a public offering in any country or jurisdiction,
other than the United States, where any such action is required, including in
Belgium. Belgian investors, other than qualified investors within the meaning
of the Belgian Act of 16 June 2006 on the public offering of securities and
the admission of securities to be traded on a regulated market (the "Belgian
Prospectus Act"), will not be eligible to participate in the offering
(whether in Belgium or elsewhere). The transaction to which this press
release relates will only be available to, and will be engaged in only with,
in member states of the European Economic Area, persons falling within the
meaning of Article 2(1)(e) of the Prospectus Directive 2003/71/EC as amended
by Directive 2010/73/EU, and in the United Kingdom, investment professionals
falling within article 19 (5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order"), persons falling within
article 49 (2), (a) to (d) of the Order and other persons to whom it may
lawfully be communicated. A prospectus will be prepared by the TiGenix in
accordance with Article 20 of the Belgian Prospectus Act for the purpose of
having the new shares that will be represented by the ADSs admitted to
trading on Euronext Brussels.

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TiGenix via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.